PARP Inhibitors in Ovarian Cancer

doi 10.5772/52888
Full Text
Abstract

Available in full text

Date
Authors
Publisher

InTech

Related search

Extending the Scope of PARP Inhibitors in Ovarian Cancer

The Lancet Oncology
Oncology
2019English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

PARP Inhibitors in Ovarian Cancer: Sensitivity Prediction and Resistance Mechanisms

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

The Development of PARP Inhibitors in Ovarian Cancer: From Bench to Bedside

British Journal of Cancer
Cancer ResearchOncology
2015English

PARP Inhibitor Treatment in Ovarian and Breast Cancer

Current Problems in Cancer
Cancer ResearchOncology
2011English

Candidate Synthetic Lethality Partners to PARP Inhibitors in the Treatment of Ovarian Clear Cell Cancer (Review)

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2017English

PARP Inhibitors for BRCA1/2-mutated and Sporadic Ovarian Cancer: Current Practice and Future Directions

British Journal of Cancer
Cancer ResearchOncology
2016English

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Cancer Cell
Cancer ResearchOncologyCell Biology
2011English

PARP Inhibitors and Stratified Treatment of Prostate Cancer

Expert Review of Anticancer Therapy
OncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy